DIA Report Reveals What Lies Ahead for Therapeutic Innovation and Regulatory Science in North America

Share Article

DIA today unveiled its first annual “What Lies Ahead” report, providing experts’ insight into the year ahead for pharmaceuticals, biotechnology, and the product development of medical devices.

DIA, Drug Information Association
Susan Cantrell, Director, North America at DIA said, “We are excited to provide insights into where the industry is heading each year and what may continue to grow in importance over the next few years...

DIA today unveiled its first annual “What Lies Ahead” report, providing experts’ insight into the year ahead for pharmaceuticals, biotechnology, and the product development of medical devices.

With thought leaders from industry and academia asked to choose the trends they foresee shaping the world of medical product development in 2013, most agreed that the number one trend for this year will be “new models of innovation.” Based on the report, it is highly anticipated that industry will focus on collaboration and partnerships which are becoming the new norm for therapeutic research and development as companies look to capitalize on innovations outside their own walls. The report points to shrinking industry R&D budgets as being a motivator for such partnerships. The desire to reduce the time to market for urgently needed medicines and to avoid needlessly exposing patients to previously failed approaches were highlighted as strong motivators as well.

Susan Cantrell, Director, North America at DIA said, “We are excited to provide insights into where the industry is heading each year and what may continue to grow in importance over the next few years. These projections of the future landscape can be valuable to companies as they strategize to successfully meet the ever-changing needs of the marketplace.”

The study shows expectations of 2013 are that of the continued strengthening of consumer/patient empowerment (second most expected trend), a focus on unmet medical needs as the driver for innovations, and growing regulatory cooperation and convergence across multiple regions.

“While this study is specific to North America, and the United States in particular, as the global forum for therapeutic innovation and regulatory science we anticipate it being useful on a worldwide scale,” said Cantrell.

To obtain a copy of the study or to interview a respondent, please contact Eric Rosen at eric.rosen(at)diahome(dot)org or at 215.290-9153.

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, PA., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C. and Latin America. Visit our website at http://www.diahome.org; follow DIA on Facebook, Twitter (#druginfoassn), LinkedIn, Flickr and YouTube.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website